Business Wire

Introducing The Continental Edge: The Easternmost Direct Interconnectivity Point Between Europe and the United States

Share

Introducing the Continental Edge, the easternmost direct interconnection point between Europe and the United States. Four companies, focused on four key areas of services, have partnered to offer the first holistic solution that delivers best-of-breed colocation, connectivity, internet, and subsea cable solutions. The partnership is an amalgamation of companies brought to market collectivity by 1025Connect (for colocation); Aqua Comms (transatlantic subsea connectivity); DE-CIX (the leading Internet Peering Exchange), and Epsilon (a global network service provider providing on-demand SDN connectivity solutions).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181023005054/en/

The Continental Edge Map (Graphic: Business Wire)

The Continental Edge Map (Graphic: Business Wire)

1025Connect’s data center and colocation facilities serves as the central point where Aqua Comms' AEC-1 cable lands and Epsilon and DE-CIX platforms are available. Any customer connected to Epsilon’s leading SDN platform, Infiny, can now design, provision, and manage network connectivity from its dense European footprint across AEC-1, the shortest subsea route between the United States and Ireland. This consists of inter datacenter, cloud or internet exchange connections, including to the leading internet exchange DE-CIX. DE-CIX customers can leverage the company’s direct peering options or its GlobePEER Remote capabilities to reach more than 1,100 unique global networks with nearly 200 locally available directly from 1025Connect’s Long Island data center.

All four partners will be attending Capacity Europe from 23-25, October 2018. To request a meeting with 1025Connect, Aqua Comms, DE-CIX, or Epsilon at Capacity Europe please email: continentaledge@imillerpr.com.

1025Connect

1025Connect is Long Island’s premier network-neutral Meet-Me Room for network interconnection and colocation, located at 1025 Old Country Road in Westbury, New York. This facility is renowned for its ability to connect global subsea systems to terrestrial networks with the optional ability to bypass Manhattan for greater network diversity and serves as host to the easternmost peering point in the New York metro area, enabling easier access and delivery of content distributed to the Continental Edge.

Aqua Comms

Aqua Comms DAC is an Irish Carriers’ Carrier specialising in building and operating submarine cable systems and supplying fibre pairs, spectrum and capacity networking solutions to the global media, content and carrier markets. It is the owner/operator of America Europe Connect-1 (AEC-1) and CeltixConnect-1 and continues to build on its vision of efficient submarine infrastructure ownership with membership of the HAVFRUE consortium and development of CeltixConnect-2 and North Sea Connect, bridging the Northern Atlantic between North America and Europe. To learn more about Aqua Comms and its portfolio of subsea cable systems visit http://www.aquacomms.com/.

DE-CIX North America

With access to DE-CIX North America’s leading Internet Exchange Platform, operators gain more control of their networks and access to world-class content providers, as well as IP transit, Virtual Private Network (VPN) and blackholing services to mitigate the effects of DDoS attacks. DE-CIX’s presence at 1025Connect provides direct access to the most robust, meshed IXP serving the New York metro market. Now customers can access close to 200 unique networks across the largest Internet Exchange Point and the only Open-IX certified IXP in the New York Market. Extend reach across the DE-CIX platform through its GlobePEER Remote solution to reach over 800 unique networks at DE-CIX Frankfurt, the world’s leading Internet Exchange by data traffic.

Epsilon

Epsilon is a global Cloud-centric Network Service Provider, extending carrier grade connectivity services to the world’s communications and cloud ecosystems. The company offers smart networking capabilities through its simple and powerful SDN platform, Infiny, that combines on-demand infrastructure, automation, web-based portals and APIs to give partners friction-free access to global connectivity.

Situated within 1025Connect, Infiny is now the easternmost SDN exchange in the USA. A connection to Epsilon provides customers access to an interconnected mesh of 100 datacenters across North America, Europe, Asia and the Middle East. Leveraging Aqua Comms’ network across the Atlantic coupled with direct connections to the leading Cloud and Internet Exchange (IX) providers including DE-CIX North America, Epsilon delivers orchestrated connectivity for advanced IX peering, cloud and content networking.

Contact information

Ilissa Miller
iMiller Public Relations
Tel: +1.866.307.2510
Email: pr@imillerpr.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 20:59:00 EESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 16:05:00 EESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 15:30:00 EESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 14:00:00 EESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 13:46:00 EESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 13:00:00 EESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom